Subscribe
Logo small
Search
banner

Dialogue is key in the work on the new reimbursement act

MedExpress Team

Piotr Wójcik

Published Nov. 21, 2022 14:00

Dialogue is key in the work on the new reimbursement act - Header image
Fot. Getty Images/iStockphoto
- There is a lack of dialogue and partner exchange of opinions - this is how Michał Byliniak, director of the General Employers' Association of Innovative Pharmaceutical Companies, INFARMA, says about the work on the Major Amendment to the Reimbursement Act. Meanwhile, the new act is being drafted with the intention of being in force for the next ten years. This means a big challenge, because it is necessary to secure the possibility of meeting the needs that will appear even in a few years.

The forthcoming amendment to the Reimbursement Act is an extensive change, made after ten years of functioning of this legal act in its current form. As emphasized by Michał Byliniak, the challenges faced by the pharmaceutical industry after the changes will be numerous, which is why it was necessary to discuss the amendments by each party. However, such a dialogue was lacking.

– The current shape of the project does not fully reflect our thoughts. We referred to him and for a long time we did not get an answer. We were convinced that there would be more of these consultations, but that did not happen. Last week, another version of the draft was published, signed with a date from a month ago, but it is not known whether it is a version that realistically reflects the arrangements m...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.